Brind.

Viking Therapeutics completed enrollment in its Phase 2 trial and initiated the VANQUISH Phase 3 registration program for its drug VK2735.

4 reports, 2 independent Updated Oct 14
Gone quiet
Reports
4
Developments
1
Repetition
75%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Viking Therapeutics completed enrollment in its Phase 2 trial and initiated the VANQUISH Phase 3 registration program for its drug VK2735.

Who's involved

What this event is mainly about
Viking Therapeutics

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • prnewswire.com
  • prnewswire.com
  • GuruFocus.comViking Therapeutics Inc (VKTX) Q2 2025 Earnings Call Highlights: Navigating Increased R&D ... Research and Development Expenses: $60.2 million for Q2 2025, up from $23.8 million in Q2 2024. General a
  • Unknown outlet